AU2004210127B2 - Substituted pyrazoles, compositions containing such compounds and methods of use - Google Patents

Substituted pyrazoles, compositions containing such compounds and methods of use Download PDF

Info

Publication number
AU2004210127B2
AU2004210127B2 AU2004210127A AU2004210127A AU2004210127B2 AU 2004210127 B2 AU2004210127 B2 AU 2004210127B2 AU 2004210127 A AU2004210127 A AU 2004210127A AU 2004210127 A AU2004210127 A AU 2004210127A AU 2004210127 B2 AU2004210127 B2 AU 2004210127B2
Authority
AU
Australia
Prior art keywords
optionally substituted
groups
group
halo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004210127A
Other languages
English (en)
Other versions
AU2004210127A1 (en
Inventor
Teresa Beeson
Emma Parmee
Subharekha Raghavan
Dong-Ming Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004210127(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2004210127A1 publication Critical patent/AU2004210127A1/en
Application granted granted Critical
Publication of AU2004210127B2 publication Critical patent/AU2004210127B2/en
Priority to AU2009240856A priority Critical patent/AU2009240856A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2004210127A 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use Ceased AU2004210127B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009240856A AU2009240856A1 (en) 2003-01-27 2009-11-26 Substituted pyrazoles, compositions containing such compounds and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44282803P 2003-01-27 2003-01-27
US60/442,828 2003-01-27
PCT/US2004/001927 WO2004069158A2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009240856A Division AU2009240856A1 (en) 2003-01-27 2009-11-26 Substituted pyrazoles, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
AU2004210127A1 AU2004210127A1 (en) 2004-08-19
AU2004210127B2 true AU2004210127B2 (en) 2009-10-01

Family

ID=32850762

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004210127A Ceased AU2004210127B2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use
AU2009240856A Abandoned AU2009240856A1 (en) 2003-01-27 2009-11-26 Substituted pyrazoles, compositions containing such compounds and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009240856A Abandoned AU2009240856A1 (en) 2003-01-27 2009-11-26 Substituted pyrazoles, compositions containing such compounds and methods of use

Country Status (8)

Country Link
US (2) US7572922B2 (enExample)
EP (1) EP1590336B1 (enExample)
JP (2) JP4560035B2 (enExample)
AT (1) ATE490244T1 (enExample)
AU (2) AU2004210127B2 (enExample)
CA (1) CA2513102C (enExample)
DE (1) DE602004030318D1 (enExample)
WO (1) WO2004069158A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
US7649009B2 (en) 2004-07-07 2010-01-19 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
ATE468853T1 (de) * 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
US7709658B2 (en) * 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101415683B (zh) 2006-03-31 2013-07-17 诺瓦提斯公司 新化合物
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2178858B1 (en) * 2007-08-02 2011-12-28 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EP2210876B1 (en) 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
NZ586190A (en) 2007-12-26 2013-05-31 Elster Electricity Llc A utility meter network wherein meters can transmit electrical and other readings to a collector by using other meters as repeaters
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009140342A1 (en) * 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
WO2010007943A1 (ja) * 2008-07-17 2010-01-21 旭化成ファーマ株式会社 含窒素複素環化合物
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR073412A1 (es) * 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
EP2344467A1 (en) * 2008-10-10 2011-07-20 Lonza Ltd. Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
CN107021951B (zh) * 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
CN103402515B (zh) 2010-11-09 2017-05-17 铁木医药有限公司 sGC刺激剂
RU2013127611A (ru) 2010-12-23 2015-01-27 Пфайзер Инк. Модуляторы глюкагонового рецептора
MX2013009140A (es) 2011-02-08 2013-10-01 Pfizer Moduladores del receptor de glucagon.
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TWI757332B (zh) * 2016-09-06 2022-03-11 比利時商健生藥品公司 使用作為升糖素受體拮抗劑之吲唑衍生物
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
CA3243048A1 (en) * 2021-12-23 2025-04-08 Vib Vzw 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
BE1009189A3 (fr) * 1995-03-14 1996-12-03 Solvay Procede pour la fabrication d'un corps creux.
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP2001504489A (ja) 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド トリアリール置換イミダゾール及び使用方法
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
CA2274592C (en) 1996-12-12 2007-03-13 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
GEP20022812B (en) 1997-04-18 2002-10-25 Searle & Co Using Cyclooxygenase-2 Inhibitors for Preparing Medicinal Means to Prevent Cardiovascular Disorders Connected with Inflammation Processes and Pharmaceutical Compositions Containing These Inhibitors
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
CN1284945A (zh) 1997-12-19 2001-02-21 安姆根有限公司 取代的吡啶和哒嗪化合物及其药物用途
IL141786A0 (en) 1998-09-17 2002-03-10 Bristol Myers Squibb Co A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
PL352367A1 (en) 1999-05-17 2003-08-25 Novo Nordisk As Glucagon antagonists/inverse agonists
JP2003506443A (ja) 1999-08-10 2003-02-18 バイエルクロップサイエンス株式会社 除草性テトラゾリノン誘導体
DK1228067T3 (da) * 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
AU2001265834A1 (en) 2000-06-23 2002-01-08 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
KR100926839B1 (ko) 2002-02-01 2009-11-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 ２－퓨란 카르복시산 하이드라지드 화합물 및 그것을함유하는 의약 조성물
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
MXPA05000816A (es) 2002-07-19 2005-04-28 Baxter Int Sistemas y metodos para realizar dialisis peritoneal.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
US20060116366A1 (en) 2002-12-04 2006-06-01 Parmee Emma R Spirocyclic ureas, compositions containing such compounds and methods of use
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EA200501607A1 (ru) 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
DE10317108A1 (de) 2003-04-14 2004-11-11 Mutzbauer, Till S., Dr. Dr.med. Transdermal applizierbares Beruhigungs- und Sedierungsmittel
JP2006528687A (ja) 2003-05-09 2006-12-21 メルク　エンド　カムパニー　インコーポレーテッド ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
ATE468853T1 (de) * 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
AU2009240856A1 (en) 2009-12-17
US20060084681A1 (en) 2006-04-20
JP2010150267A (ja) 2010-07-08
AU2004210127A1 (en) 2004-08-19
ATE490244T1 (de) 2010-12-15
DE602004030318D1 (de) 2011-01-13
CA2513102A1 (en) 2004-08-19
JP4560035B2 (ja) 2010-10-13
WO2004069158A2 (en) 2004-08-19
EP1590336A2 (en) 2005-11-02
EP1590336A4 (en) 2008-12-17
WO2004069158A3 (en) 2005-01-20
EP1590336B1 (en) 2010-12-01
JP2006516622A (ja) 2006-07-06
US20090215825A1 (en) 2009-08-27
JP5260569B2 (ja) 2013-08-14
US7572922B2 (en) 2009-08-11
US7989475B2 (en) 2011-08-02
CA2513102C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
AU2004210127B2 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
AU2005272043B2 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
AU2005269792B9 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
US7803951B2 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2006303986B2 (en) Acyl indoles, compositions containing such compounds and methods of use
JP2006528687A (ja) ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
CA2508581A1 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
AU2007254329A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR102323876B1 (ko) 신규한 항균성 화합물
JP2007501790A (ja) スルホニル置換ｎ−（ビアリールメチル）アミノシクロプロパンカルボキサミド
JP2025521596A (ja) Ｍａｓ関連ｇタンパク質受容体ｄのモジュレーターとしてのトリアゾール誘導体
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
WO2017215586A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
HK1048305B (en) Bradykinin b1 receptor antagonists
HK1048305A1 (en) Bradykinin b1 receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired